Comparison of Two Injection Treatments for Long-Term Unexplained Skin Allergy (Chronic Urticaria)

A Randomized Controlled trial of Subcutaneous Autologous Serum Therapy versus Subcutaneous Histoglobulin Injection in treatment of Idiopathic Chronic Urticaria. - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/06/088916

Enrollment

Registered

2025-06-16

Start date

Unknown

Completion date

Unknown

Last updated

2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L501- Idiopathic urticaria

Interventions

Intervention1: Subcutaneous Autologous Serum Therapy: Subcutaneous Autologous Serum Therapy AST Participants in this group will receive subcutaneous injections of their own serum (autologous serum) wh

Eligibility

Inclusion criteria

Inclusion criteria: Patients greater than 18 Years of Age. Patients who are Diagnosed with chronic Idiopathic Urticaria.

Exclusion criteria

Exclusion criteria: Patients who are hypersensitive to Histoglobulin or its components. Patients will be excluded if they have an active infection. Patients with Autoimmune diseases and Malignancy. Pregnant and lactating females Patients with Acute Exacerbation of Urticaria.

Design outcomes

Primary

Measure	Time frame
To compare the Efficacy of subcutaneous Autologous serum therapy(AST) versus subcutaneous Histoglobulin injection in reducing symptoms of Idiopathic chronic urticariaTimepoint: Assessed at an interval of 1 week for 6 weeks and will be followed once a week for next 4 weeks	—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDr Yeragonda Susmitha

Sri Devaraj URS Academy of Higher Education and Research

drsushmithareddy1696@gmail.com8522899673

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026